Biosimilars Deals 2020
10 Nov 2020 | Prestige BioPharma, Teva Israel | Prestige BioPharma and Teva Israel announce they have entered into an exclusive partnership and supply agreement for Prestige's Tuznue® (trastuzumab biosimilar) in Israel. Under the agreement, Prestige is responsible for registration and commercial supply, and Teva Israel will be responsible for local registration, sales and marketing in Israel.
07 Nov 2020 | Biocon Biologics, Goldman Sachs | Biocon Biologics announces it has approved a USD 150 million capital injection from Goldman Sachs. Dr Christiane Hamacher (CEO of Biocon Biologics) announced that this capital injection will enable Biocon Biologics to make prudent investments in R&D, high-quality manufacturing and establishing a global commercial footprint.
04 Nov 2020 | Alvotech, Cipla | Alvotech announces it has entered into an exclusive partnership with Cipla for two oncology biosimilars and three auto-immune biosimilars in South Africa. Under the agreement, Alvotech will be responsible for the development and supply of the products, while Cipla will be responsible for registration and commercialisation.
30 Oct 2020 | Ocumension Therapeutics, Shandong Boan Biological Therapeutics| Ocumension Therapeutics announces it has reached an agreement with Shandong Boan Biological Technology to jointly develop OT-702, a proposed aflibercept biosimilar. Under the agreement, Ocumension has been granted an exclusive license to promote and commercialise the product in mainland China. OT-702 is currently in Ph III trials.
29 Oct 2020 | SomaLogic, FDA | SomaLogic announces it has signed an agreement with the FDA for the large-scale analysis of proteins for the identification of biomarkers that may be useful in demonstrating biosimilarity of a proposed biosimilar and a reference product. It is hoped that the five year collaboration will streamline the development of biosimilars by reducing the need for comparative clinical studies, thus accelerating the delivery of safe, effective and affordable biosimilar treatments.
27 Oct 2020 | Alvotech | Alvotech announces that its parent company, Alvotech Holdings SA, has successfully completed a $65 million private placement round, which will further finance the development and release of its biosimilar candidates. This $65 million round is part of a larger $100 million round, with a second round expected to close shortly. The new share issue values Alvotech at $1.5 billion.
05 Oct 2020 | Medicure, Reliance Life Sciences | Medicure announces it has entered a License, Manufacture and Supply Agreement with Reliance Life Sciences for a cardiovascular biosimilar product for EU, US and Canada. Medicure is responsible for the regulatory approval process for that product.
22 Sep 2020 | Alvotech, DKSH | Alvotech announces an expansion of its strategic partnership with DKSH to commercialise six new biosimilar product candidates for Asian markets, including Taiwan, Korea, Hong Kong, Philippines, Vietnam, Thailand, Cambodia, Myanmar, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan. These biosimilar candidates’ brand values are estimated around US$1.5 billion in annual sales in the Asia Pacific region, according to IQVIA data.. The biosimilar candidates will address multiple therapeutic areas and represent an estimated (combined) US$1.5 billion in annual sales in the Asia Pacific region.
20 Aug 2020 | Intract Pharma, Celltrion | Intract Pharma and Celltrion announce an agreement to jointly develop the world's first oral antibody therapeutic for the treatment of IBD. The infliximab product has been cleared by the UK's MHRA to proceed to Ph 1b/2a clinical trials in patients with IBD during the second half of 2021.
05 Aug 2020 | Alvotech, Teva | Alvotech and Teva announce a strategic partnership to collaborate on five biosimilar product candidates in the US market. Under the agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercialising the products in the US. The agreement includes an upfront payment, with subsequent milestone payments, with Alvotech and Teva to share the profits from commercialisation.
17 Jul 2020 | VentureTECH, Duopharma and PanGen | VentureTECH, Duopharma and PanGen Biotech announce a joint venture to develop a Malaysian biosimilar production facility.
17 Jul 2020 | Bio-Thera Solutions, Pharmapark | Bio-Thera Solutions annnounces a licensing agreement with Pharmapark for BAT2506 (biosimilar golimumab candidate). Under the agreement, Pharmapark will have exclusive rights to distribute and market the drug in Russia and other CIS countries.
25 June 2020 | AbbVie, Sosei Heptares | Abbvie and Sosei Heptares announce a $409M deal to discover and develop new immunology drugs. The agreement covers the drug-discovery, development and commercialisation of small-molecule medicines that target autoimmune and inflammatory diseases using the G protein-coupled receptor. AbbVie will pay Sosei Heptares up to $32M upfront and at milestones for an additional $377M, along with royalties.
11 June 2020 | Celltrion, Takeda | Celltrion announces a $278 million deal to acquire Takeda Pharmaceuticals Primary Care businesses in the Asia Pacific. Under the agreement, Celltrion will gain access to patent, trademark and marketing rights for 18 prescription and over-the-counter brands in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Singapore and Australia.
08 May 2020 | AbbVie, Allergan | AbbVie announces it has completed its acquisition of Allergan, following regulatory approval from all relevant Government agencies. AbbVie will now have access to Allergan's neuroscience products including Vraylar® and Ubrelvy®, and aesthetic products including the Botox® and Juvederm® brands.
15 Jan 2020 | Alvotech, JAMP Pharma | Alvotech and JAMP announce agreement to commercialise five biosimilar products in Canada.
13 Jan 2020 | Mundipharma, Samsung | Mundipharma announces commercialisation agreement with Samsung. The agreement grants Mundipharma exclusive commercialisation rights to Samsung's adalimumab, etanercept, trastuzumab and bevacizumab candidates in Taiwan and Hong Kong.